查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179734

骨肉瘤治疗市场：按类型、按药物类型、按分销渠道：全球机会分析和行业预测，2021-2031 年

Bone Cancer Treatment Market By Type, By Drug type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 294 Pages | 商品交期: 2-3个工作天内

价格

2021年全球骨肉瘤治疗市场规模将达到11.8254亿美元，2031年将达到18.3136亿美元，2022-2031年復合年增长率为4.5%，预计将继续增长。

骨肉瘤是起源于骨骼的多种癌症之一。 它是由骨骼中异常细胞不受控制的生长引起的。 根除健康的骨组织。 骨肉瘤的治疗包括免疫疗法、靶向疗法、化学疗法、放射疗法和手术。

推动骨肉瘤治疗市场增长的主要因素是政府加大努力提高人们对骨肉瘤治疗的认识、骨肉瘤发病率上升以及产品发布和批准激增。 此外，越来越多地使用靶向疗法、药物个性化和新兴市场的增长机会也是预计在预测期内推动增长的主要市场趋势。

产品发布和批准的显着激增是该市场的主要驱动力之一，因为产品发布创造了推动市场增长的新机会。 例如，2021年5月，CancerVax, Inc.正与加州大学洛杉矶分校（UCLA）合作，研发针对尤文肉瘤治疗的突破性免疫疗法。 这是一种罕见但致命的软组织和骨骼癌症，主要影响儿童和年轻人。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 主要公司的定位
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • COVID-19 影响分析

第 4 章骨肉瘤治疗市场：按类型

  • 概览
    • 市场规模和预测
  • 骨肉瘤
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 软骨肉瘤
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 尤文肉瘤
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
    • 尤文肉瘤的骨肉瘤治疗市场：按年龄组分类
      • 45 岁以下市场规模和预测：按地区
      • 45 岁及以上人群的市场规模和预测：按地区
  • 其他
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 5 章骨肉瘤治疗市场：按药物类型分类

  • 概览
    • 市场规模和预测
  • 免疫疗法和靶向疗法
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 化疗
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 6 章骨肉瘤治疗市场：按分销渠道

  • 概览
    • 市场规模和预测
  • 医院药房
    • 主要市场趋势、增长因素和机遇
    • 市场规模/预测：按地区
    • 市场分析：按国家/地区分类
  • 药店和零售药店
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 在线药店
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 7 章骨肉瘤治疗市场：按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机会
    • 北美市场规模和预测：按类型
      • 北美尤文肉瘤骨肉瘤治疗市场：按年龄组分类
    • 北美市场规模和预测：按药物类型
    • 北美市场规模和预测：按分销渠道
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机会
    • 欧洲市场规模和预测：按类型
      • 欧洲尤文肉瘤骨肉瘤治疗市场：按年龄组分类
    • 欧洲尤文氏肉瘤骨肉瘤市场规模和预测：按药物类型
    • 欧洲市场规模和预测：按分销渠道
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲地区
  • 亚太地区
    • 主要趋势和机会
    • 亚太市场规模和预测：按类型
      • 亚太地区尤文肉瘤骨肉瘤治疗市场：按年龄组分类
    • 亚太地区市场规模和按药物类型预测
    • 亚太市场规模和预测：按分销渠道
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 日本
      • 中国
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
  • 拉美
    • 主要趋势和机会
    • LAMEA 市场规模和预测：按类型
      • LAMEA 尤因肉瘤骨肉瘤治疗市场：按年龄组分类
    • LAMEA 市场规模和预测：按药物类型
    • LAMEA 市场规模和预测：按分销渠道
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其余部分

第八章公司情况

  • 简介
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第九章公司简介

  • Advaxis, Inc
  • Takeda Pharmaceutical Company Limited
  • Cancervax, Inc
  • Cellectar Biosciences, Inc
  • Pfizer, Inc
  • Isofol Medical Ab
  • Gradalis Inc
  • Hikma Pharmaceutical PLC
  • QSAM Biosciences, Inc.
  • Zentalis Pharmaceuticals
Product Code: A17520

The global bone cancer treatment market was valued at $1,182.54 million in 2021, and is estimated to reach $1,831.36 million by 2031, growing at a CAGR of 4.5% from 2022 to 2031. Bone cancer is one of numerous types of cancers that originates in the bones. It develops when abnormal cells proliferate uncontrollably in bone. It eradicates healthy bone tissues. Treatment for bone cancer includes immunotherapy, targeted therapies, chemotherapy, radiation therapy, and surgery.

Major factors that drive growth of the bone cancer treatment market is increase in government initiatives to create awareness for bone cancer treatment, rise in incidences of bone cancer, and surge in product launches and product approvals. In addition, increase in utilization for targeted therapies, personalization of medicines, and growth opportunities in emerging markets is a key trend of the market, which is expected to fuel growth during the the forecast period.

Significant surge in product launches and approvals is one of the leading factors of this market as product launch creates new opportunities to propel the market growth. For instance, in May 2021 CancerVax, Inc along with University of California Los Angeles ("UCLA") to research and develop an immunotherapy breakthrough targeted at treating Ewing sarcoma. This is a rare but deadly soft tissue and bone cancer that primarily affects children and young adults.

In addition, various government organizations are taking initiatives to create awareness regarding the treatment of bone cancer. However high cost of drugs and diagnosis is expected to hinder growth of the market. Moreover, launch of various bone cancer treatment products to suffice consumer demands in developing countries is expected to provide a great opportunity for investors to invest in the market.

The global bone cancer treatment market is segmented on the basis of type, drug type, distribution channel, and region. On the basis of type, the market is categorized into osteosarcoma, chondrosarcoma, Ewing sarcoma and others. The Ewing sarcoma is further segmented on the basis of age group into below 45 and above 45. By drug type, it is divided into immunotherapy & targeted therapy and chemotherapy. By distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

The major players profiled in the report are Advaxis Inc., CancerVax, Inc, Cellectar Biosciences, Inc, Isofol Medical Ab, Pfizer Inc, Takeda Pharmaceutical Company Limited, Gradalis Inc. Hikma Pharmaceutical PLC, QSAM Biosciences, Inc., and Zentalis Pharmaceuticals.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bone cancer treatment market analysis from 2021 to 2031 to identify the prevailing bone cancer treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the bone cancer treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global bone cancer treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Osteosarcoma
  • Chondrosarcoma
  • Ewing Sarcoma
    • Age group
    • Below 45
    • Above 45
  • Others

By Drug type

  • Immunotherapy and Targeted Therapy
  • Chemotherapy

By Distribution Channel

  • Hospital Pharmacies
  • Drug Store and Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Advaxis, Inc
    • Takeda Pharmaceutical Company Limited
    • Cancervax, Inc
    • Cellectar Biosciences, Inc
    • Pfizer, Inc
    • Isofol Medical Ab
    • Gradalis Inc
    • Hikma Pharmaceutical PLC
    • QSAM Biosciences, Inc.
    • Zentalis Pharmaceuticals

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: BONE CANCER TREATMENT MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Osteosarcoma
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Chondrosarcoma
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Ewing Sarcoma
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
    • 4.4.4 Ewing Sarcoma Bone Cancer Treatment Market by Age group
      • 4.4.4.1 Below 45 Market size and forecast, by region
      • 4.4.4.2 Above 45 Market size and forecast, by region
  • 4.5 Others
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country

CHAPTER 5: BONE CANCER TREATMENT MARKET, BY DRUG TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Immunotherapy and Targeted Therapy
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Chemotherapy
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Drug Store and Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online Pharmacies
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: BONE CANCER TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Type
      • 7.2.2.1 North America Ewing Sarcoma Bone Cancer Treatment Market by Age group
    • 7.2.3 North America Market size and forecast, by Drug type
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Type
      • 7.2.5.1.2 Market size and forecast, by Drug type
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Type
      • 7.2.5.2.2 Market size and forecast, by Drug type
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Type
      • 7.2.5.3.2 Market size and forecast, by Drug type
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Type
      • 7.3.2.1 Europe Ewing Sarcoma Bone Cancer Treatment Market by Age group
    • 7.3.3 Europe Market size and forecast, by Drug type
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Type
      • 7.3.5.1.2 Market size and forecast, by Drug type
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Type
      • 7.3.5.2.2 Market size and forecast, by Drug type
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Type
      • 7.3.5.3.2 Market size and forecast, by Drug type
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Type
      • 7.3.5.4.2 Market size and forecast, by Drug type
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Type
      • 7.3.5.5.2 Market size and forecast, by Drug type
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Type
      • 7.3.5.6.2 Market size and forecast, by Drug type
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Type
      • 7.4.2.1 Asia-Pacific Ewing Sarcoma Bone Cancer Treatment Market by Age group
    • 7.4.3 Asia-Pacific Market size and forecast, by Drug type
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Type
      • 7.4.5.1.2 Market size and forecast, by Drug type
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Type
      • 7.4.5.2.2 Market size and forecast, by Drug type
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Type
      • 7.4.5.3.2 Market size and forecast, by Drug type
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Market size and forecast, by Type
      • 7.4.5.4.2 Market size and forecast, by Drug type
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Type
      • 7.4.5.5.2 Market size and forecast, by Drug type
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Type
      • 7.4.5.6.2 Market size and forecast, by Drug type
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Type
      • 7.5.2.1 LAMEA Ewing Sarcoma Bone Cancer Treatment Market by Age group
    • 7.5.3 LAMEA Market size and forecast, by Drug type
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Type
      • 7.5.5.1.2 Market size and forecast, by Drug type
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Type
      • 7.5.5.2.2 Market size and forecast, by Drug type
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Type
      • 7.5.5.3.2 Market size and forecast, by Drug type
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Type
      • 7.5.5.4.2 Market size and forecast, by Drug type
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Advaxis, Inc
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Takeda Pharmaceutical Company Limited
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Cancervax, Inc
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Cellectar Biosciences, Inc
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Pfizer, Inc
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Isofol Medical Ab
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Gradalis Inc
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Hikma Pharmaceutical PLC
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 QSAM Biosciences, Inc.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Zentalis Pharmaceuticals
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 2. BONE CANCER TREATMENT MARKET, FOR OSTEOSARCOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. BONE CANCER TREATMENT MARKET FOR OSTEOSARCOMA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. BONE CANCER TREATMENT MARKET, FOR CHONDROSARCOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. BONE CANCER TREATMENT MARKET FOR CHONDROSARCOMA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. BONE CANCER TREATMENT MARKET, FOR EWING SARCOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. BONE CANCER TREATMENT MARKET FOR EWING SARCOMA, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. GLOBAL EWING SARCOMA BONE CANCER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 9. BONE CANCER TREATMENT MARKET, FOR BELOW 45, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. BONE CANCER TREATMENT MARKET, FOR ABOVE 45, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. BONE CANCER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. BONE CANCER TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. GLOBAL BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 14. BONE CANCER TREATMENT MARKET, FOR IMMUNOTHERAPY AND TARGETED THERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. BONE CANCER TREATMENT MARKET FOR IMMUNOTHERAPY AND TARGETED THERAPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. BONE CANCER TREATMENT MARKET, FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. BONE CANCER TREATMENT MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. GLOBAL BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 19. BONE CANCER TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. BONE CANCER TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. BONE CANCER TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. BONE CANCER TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 23. BONE CANCER TREATMENT MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 24. BONE CANCER TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 25. BONE CANCER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 26. NORTH AMERICA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA EWING SARCOMA BONE CANCER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA BONE CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 31. U.S. BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 32. U.S. BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 33. U.S. BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 34. CANADA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 35. CANADA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 36. CANADA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 37. MEXICO BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 38. MEXICO BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 39. MEXICO BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 40. EUROPE BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 41. EUROPE EWING SARCOMA BONE CANCER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 42. EUROPE BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 43. EUROPE BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 44. EUROPE BONE CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 45. GERMANY BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 46. GERMANY BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 47. GERMANY BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 48. FRANCE BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 49. FRANCE BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 50. FRANCE BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 51. UK BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 52. UK BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 53. UK BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 54. ITALY BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 55. ITALY BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 56. ITALY BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 57. SPAIN BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 58. SPAIN BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 59. SPAIN BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 60. REST OF EUROPE BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 61. REST OF EUROPE BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 62. REST OF EUROPE BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 63. ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 64. ASIA-PACIFIC EWING SARCOMA BONE CANCER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 66. ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 67. ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 68. JAPAN BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 69. JAPAN BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 70. JAPAN BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 71. CHINA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 72. CHINA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 73. CHINA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 74. INDIA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 75. INDIA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 76. INDIA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 77. AUSTRALIA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 78. AUSTRALIA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 79. AUSTRALIA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 80. SOUTH KOREA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH KOREA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH KOREA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 83. REST OF ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 84. REST OF ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 85. REST OF ASIA-PACIFIC BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 86. LAMEA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 87. LAMEA EWING SARCOMA BONE CANCER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 88. LAMEA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 89. LAMEA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 90. LAMEA BONE CANCER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 91. BRAZIL BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 92. BRAZIL BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 93. BRAZIL BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 94. SAUDI ARABIA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 95. SAUDI ARABIA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 96. SAUDI ARABIA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 97. SOUTH AFRICA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 98. SOUTH AFRICA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 99. SOUTH AFRICA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 100. REST OF LAMEA BONE CANCER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 101. REST OF LAMEA BONE CANCER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 102. REST OF LAMEA BONE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 103.ADVAXIS, INC: COMPANY SNAPSHOT
  • TABLE 104.ADVAXIS, INC: OPERATING SEGMENTS
  • TABLE 105.ADVAXIS, INC: PRODUCT PORTFOLIO
  • TABLE 106.ADVAXIS, INC: NET SALES,
  • TABLE 107.ADVAXIS, INC: KEY STRATERGIES
  • TABLE 108.TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 109.TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
  • TABLE 110.TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 111.TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES,
  • TABLE 112.TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
  • TABLE 113.CANCERVAX, INC: COMPANY SNAPSHOT
  • TABLE 114.CANCERVAX, INC: OPERATING SEGMENTS
  • TABLE 115.CANCERVAX, INC: PRODUCT PORTFOLIO
  • TABLE 116.CANCERVAX, INC: NET SALES,
  • TABLE 117.CANCERVAX, INC: KEY STRATERGIES
  • TABLE 118.CELLECTAR BIOSCIENCES, INC: COMPANY SNAPSHOT
  • TABLE 119.CELLECTAR BIOSCIENCES, INC: OPERATING SEGMENTS
  • TABLE 120.CELLECTAR BIOSCIENCES, INC: PRODUCT PORTFOLIO
  • TABLE 121.CELLECTAR BIOSCIENCES, INC: NET SALES,
  • TABLE 122.CELLECTAR BIOSCIENCES, INC: KEY STRATERGIES
  • TABLE 123.PFIZER, INC: COMPANY SNAPSHOT
  • TABLE 124.PFIZER, INC: OPERATING SEGMENTS
  • TABLE 125.PFIZER, INC: PRODUCT PORTFOLIO
  • TABLE 126.PFIZER, INC: NET SALES,
  • TABLE 127.PFIZER, INC: KEY STRATERGIES
  • TABLE 128.ISOFOL MEDICAL AB: COMPANY SNAPSHOT
  • TABLE 129.ISOFOL MEDICAL AB: OPERATING SEGMENTS
  • TABLE 130.ISOFOL MEDICAL AB: PRODUCT PORTFOLIO
  • TABLE 131.ISOFOL MEDICAL AB: NET SALES,
  • TABLE 132.ISOFOL MEDICAL AB: KEY STRATERGIES
  • TABLE 133.GRADALIS INC: COMPANY SNAPSHOT
  • TABLE 134.GRADALIS INC: OPERATING SEGMENTS
  • TABLE 135.GRADALIS INC: PRODUCT PORTFOLIO
  • TABLE 136.GRADALIS INC: NET SALES,
  • TABLE 137.GRADALIS INC: KEY STRATERGIES
  • TABLE 138.HIKMA PHARMACEUTICAL PLC: COMPANY SNAPSHOT
  • TABLE 139.HIKMA PHARMACEUTICAL PLC: OPERATING SEGMENTS
  • TABLE 140.HIKMA PHARMACEUTICAL PLC: PRODUCT PORTFOLIO
  • TABLE 141.HIKMA PHARMACEUTICAL PLC: NET SALES,
  • TABLE 142.HIKMA PHARMACEUTICAL PLC: KEY STRATERGIES
  • TABLE 143.QSAM BIOSCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 144.QSAM BIOSCIENCES, INC.: OPERATING SEGMENTS
  • TABLE 145.QSAM BIOSCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 146.QSAM BIOSCIENCES, INC.: NET SALES,
  • TABLE 147.QSAM BIOSCIENCES, INC.: KEY STRATERGIES
  • TABLE 148.ZENTALIS PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 149.ZENTALIS PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 150.ZENTALIS PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 151.ZENTALIS PHARMACEUTICALS: NET SALES,
  • TABLE 152.ZENTALIS PHARMACEUTICALS: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.BONE CANCER TREATMENT MARKET SEGMENTATION
  • FIGURE 2.BONE CANCER TREATMENT MARKET,2021-2031
  • FIGURE 3.BONE CANCER TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.BONE CANCER TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.BONE CANCER TREATMENT MARKET,BY TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF OSTEOSARCOMA BONE CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CHONDROSARCOMA BONE CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF EWING SARCOMA BONE CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS BONE CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 17.BONE CANCER TREATMENT MARKET,BY DRUG TYPE,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF IMMUNOTHERAPY AND TARGETED THERAPY BONE CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY BONE CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 20.BONE CANCER TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES BONE CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF DRUG STORE AND RETAIL PHARMACIES BONE CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES BONE CANCER TREATMENT MARKET,2021-2031(%)
  • FIGURE 24.BONE CANCER TREATMENT MARKET BY REGION,2021
  • FIGURE 25.U.S. BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 26.CANADA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 27.MEXICO BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.GERMANY BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.FRANCE BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.UK BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.ITALY BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.SPAIN BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.REST OF EUROPE BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.JAPAN BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.CHINA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.INDIA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.AUSTRALIA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.SOUTH KOREA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.REST OF ASIA-PACIFIC BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.BRAZIL BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.SAUDI ARABIA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.SOUTH AFRICA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 43.REST OF LAMEA BONE CANCER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 48.COMPETITIVE DASHBOARD
  • FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 50.ADVAXIS, INC.: NET SALES ,($MILLION)
  • FIGURE 51.TAKEDA PHARMACEUTICAL COMPANY LIMITED.: NET SALES ,($MILLION)
  • FIGURE 52.CANCERVAX, INC.: NET SALES ,($MILLION)
  • FIGURE 53.CELLECTAR BIOSCIENCES, INC.: NET SALES ,($MILLION)
  • FIGURE 54.PFIZER, INC.: NET SALES ,($MILLION)
  • FIGURE 55.ISOFOL MEDICAL AB.: NET SALES ,($MILLION)
  • FIGURE 56.GRADALIS INC.: NET SALES ,($MILLION)
  • FIGURE 57.HIKMA PHARMACEUTICAL PLC.: NET SALES ,($MILLION)
  • FIGURE 58.QSAM BIOSCIENCES, INC..: NET SALES ,($MILLION)
  • FIGURE 59.ZENTALIS PHARMACEUTICALS.: NET SALES ,($MILLION)